Access to orphan drugs: A comprehensive review of legislations, regulations and policies in 35 countries

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Gammie, Todd ^a   Lu, Christine Y ^b   Ud Din Babar, Zaheer ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

DRUG APPROVAL; DRUG CONTROL; DRUG COST; DRUG LEGISLATION; DRUG MARKETING; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; MEDICAL LITERATURE; PEER REVIEW; POPULATION SIZE; REIMBURSEMENT; REVIEW; REWARD; COST BENEFIT ANALYSIS; DRUG MANUFACTURE; ECONOMICS; LEGISLATION AND JURISPRUDENCE; MARKETING; MOTIVATION; RARE DISEASE;

COST-BENEFIT ANALYSIS; HEALTH POLICY; HUMANS; LEGISLATION, DRUG; MARKETING; MOTIVATION; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 84949032870     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140002     Document Type: Review

References (63)

1. Franco P. Orphan Drugs: the regulatory environment. Drug Discovery today. 2013; 18(3):163-72.
2. Aagaard L, Kristensen K. Access to cross-border health care services for patients with rare diseases in the European Union. Orphan Drugs: research and reviews. 2014:39-45.
3. Blankart A, Rudolf C, Stargardt T, Schreyogg J. Availability of and access to orphan drugs. Pharmacoeconomics. 2011; 29(1):63-82. doi: 10.2165/11539190-000000000-00000 PMID: 21073206
4. Garau M, Mestre-Ferrandiz J. Access mechanisms for orphan drugs: a comparative study of selected European countries2009. Available from: http://www.raredisease.org.uk/documents/OHEBriefingOrphanDrugs.pdf.
5. Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy. 2014.
6. Feltmate K, Janiszewski PM, Gingerich S, Cloutier M. Delayed access to treatments for rare diseases: Who's to blame? Respirology. 2015; 20(3):361-9. doi: 10.1111/resp.12498 PMID: 25722183
7. Melnikova I. Rarre diseases and orphan drugs. Nature Reviews Drug Discovery. 2012; 11(4):267-8. doi: 10.1038/nrd3654 PMID: 22460117
8. Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Reviews Pharmacoeconomics Outcomes Research. 2012; 12(1):23-9.
9. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Issues surrounding orphan disease and orphan drug policies in Europe. Applied health economics and health policy. 2010; 8(5):343-50. doi: 10.2165/11536990-000000000-00000 PMID: 20804226
10. Trama A, Pierannunzio D, Loizzo A, Taruscio D, Ceci A. Availability of medicines for rare diseases in EU countries. Pharmaceuticals Policy and Law. 2009; 11(1):101-9.
11. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine. 2009; 6(6):1-6.
12. Barak A, Nandi JS. Orphan drugs: pricing, reimbursement and patient access. International Journal of Pharmaceutical and Healthcare Marketing. 2011; 5(4):299-317.
13. Rosenburg-Yunger ZRS, Daar AS, Thorsteinsdottir H, Martin DK. Priority setting for orphan drugs: An international comparison. Health Policy. 2011; 100(1):25-34. doi: 10.1016/j.healthpol.2010.09.008 PMID: 20961647
14. Iskrov G, Stefanov R. Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerations. Orphan Drugs: Research and Reviews. 2014; 4.
15. Russell Tegarden J, Unger TF, Hirsch G. Access and availability of orphan drugs in the United States: advances or cruel hoaxes? Expert Opinion on Orphan Drugs. 2014; 2(11):1147-50.
16. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. A comparative study of European rare disease and orphan drug markets. Health Policy. 2010; 97(2):173-9.
17. Picavet E, Cassiman D, Simoens S. Reimbursement of orphan drugs in Belgium: what (else) matters? Orphanet Journal for Rare Diseases. 2014; 9(1):139.
18. Brabers AE, Moors EH, van Weely S, de Vrueh RL. Does market exclusivity hinder the development of follow-on orphan medicinal products in Europe. Orphanet Journal for Rare Diseases. 2011; 6(59).
19. Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria. Health Policy. 2012; 108(1):10-8. doi: 10.1016/j.healthpol.2012.08.013 PMID: 22939047
20. Kamusheva M, Stoimenova A, Doneva M, Zlatareva A, Petrova G. A Cross-Country Comparison of Reimbursed Orphan Medicines in Bulgaria, Greece and Romania. Biotechnology and Biotechnological Equipment. 2013; 27(5):4186-92.
21. Stefanov R, Taruscio D. Rare diseases and orphan drugs in Eastern European Countries. Italian Journal of Public Health. 2012; 6(4).
22. Pavlovic N, Stanimirov B, Stojancevic M, Paut-Kusturica M, Stoimenova A, Golocorbin-Kon S, et al. An insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden. Biotechnology and Biotechnological Equipment. 2012; 26(5):3236-41.
23. Liu BC, He L, He G, He Y. A cross-national comparative study of orphan drug policies in the United States, the European Union and Japan: Towards a made-in-China orphan drug policy. Journal of public health policy. 2010; 31(4):407-21. doi: 10.1057/jphp.2010.30 PMID: 21119648
24. Stolk P, Heemstra HE, Leufkens HGM, Bloechl-Daum B, Heerdink ER. No difference in between-country variability in use of newly approved orphan and non-orphan medicinal products - a pilot study. Orphanet Journal of Rare Diseases. 2009; 4 (1):27.
25. Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010-2020. Orphanet Journal of Rare Diseases. 2011; 6(62):1-10.
26. Tordrup D, Tzouma V, Kanavos P. Orphan Drug considerationsin Health Technology Assessment in eight European countries. Rare Diseases and Orphan Drugs: An International Journal of Public Health. 2014; 1(3):86-97.
27. Zlatareva A, Lakic D, Kamusheva M, Spaskov D, Georgi M, Guenka P. Analysis of Access to Orphan Drugs in Five Neighbouring European Countries-Bulgaria, Greece, Macedonia, Romania and Serbia. World Journal of Pharmacy and Pharmaceutical Sciences 2. 2013:4415-34.
28. Saikiran Reddy D, Pramodkumar TM, Reddy Y, Sirisha K. Orphan regulations for orphan drug development in India. Asian Jounal of Pharmaceutics. 2014; 8(2):130.
29. Picavet E, Cassiman D, Simoens S. Evaluating and improving orphan drug regulations in Europe: A Delphi policy study. Health Policy. 2012; 108(1):1-9. doi: 10.1016/j.healthpol.2012.08.023 PMID: 22989856
30. Picavet E, Morel T, Cassiman D, Simoens S. Shining a light in the black box of orphan drug pricing. Orphanet Journal for Rare Diseases. 2014; 9(1).
31. Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: Rare Disease research stimulator or commercial opportunity? Health Policy. 2010; 95(2):216-28.
32. Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs and their regulation in Asia: Current status and future perspectives. Intractable & Rare Diseases Research. 2012; 1(1):3-9. doi: 10.5582/irdr.2012.v1.1.3 PMID: 25343064
33. Logviss K, Krievins D, Purvina S. Orphan Drugs in Surgery. Acta Chirurgica Latviensis. 2013; 13 (1):57-62.
34. Logviss K, Krievins D, Purvina S, editors. Trends in individual reimbursement of orphan drugs in Latvia in 2008-20112014; Riga: EDP Sciences.
35. Sharma A, Jacob A, Tandon M, Kumar D. Orphan Drug: development trends and strategies. Journal of Pharmacy and Bioallied Sciences. 2010; 2(4):290. doi: 10.4103/0975-7406.72128 PMID: 21180460
36. Thamer M, Brennan N, Semansky R. A cross-national comparison of orphan drug policies: implications forthe US Orphan Drug Act. Journal of Health Politics, Policy and Law. 1998; 23(2):265-90. PMID: 9565894
37. Boon W, Martins L, Koopmanschap M. Governance of conditional reimbursement practices in the Netherlands. Health Policy. 2014.
38. Kockaya G, Wertheimer AI, Kilic P, Tanyeri P, Vural I, Akbulat A, et al. An Overview of the Orphan Medicines Market in Turkey. Value in Health Regional Issues 2014:47-52.
39. Drummond M, Wilson D, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. International journal of technology assessment in healthcare. 2007; 23(1):36-42. PMID: 17234015
40. Song P, Tang W, Kokudo N. Rare diseases and orphan drugs in Japan: developing multiple strategies of regulation and research. Expert Opinion on Orphan Drugs. 2013; 1(9):681-3.
41. Côte A, Keating B. What is wrong with orphan drug policies? Value in Health. 2012; 15(8):1185-91. doi: 10.1016/j.jval.2012.09.004 PMID: 23244823
42. Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. Incentives for orphan drug research and development in the United States. Orphanet Journal of Rare Diseases. 2008; 3(33):1-7.
43. Logviss L, Krievins D, Purvina S. Rare diseases and orphan drugs: Latvian Story. Orphanet Journal of Rare Diseases. 2014; 9(1).
44. Villa S, Compagni A, Reich MR. Orphan drug legislation: lessons for negleted tropical diseases. The International journal of health planning and management. 2009; 24(1):27-42. doi: 10.1002/hpm.930 PMID: 18435430
45. Hansen JC. Rare Diseases and Orphan Drugs: A comprehensive approach of strategic perspectives. Journal of Communication in Healthcare. 2012; 5(4):199-219.
46. Rollet P, Lemoine A, Dunoyer M. Sustainable rare diseases business and drug access: no time for misconceptions. Orphan Journal of Rare Diseases. 2013; 8(1):109.
47. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nature Reviews Drug Discovery. 2010; 9(12):921-9. doi: 10.1038/nrd3275 PMID: 21060315
48. Dupont AG, Van Wilder PB. Access to orphan drugs despite poor quality of clinical evidence. British Journal of clinical pharmacology. 2011; 71(4):488-96. doi: 10.1111/j.1365-2125.2010.03877.x PMID: 21395641
49. Dunoyer M. Accelerating access to treatments for rare diseases. Nature Reviews Drug Discovery. 2011; 10(7):475-6. doi: 10.1038/nrd3493 PMID: 21701499
50. Reider CR. The orphan drug act: provisions and considerations. Drug information journal. 2000:295-300.
51. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet Journal for Rare Diseases. 2011; 6(42):1-8.
52. Stolk P, Willemen MJC, Leufkens HGM. Rare Essentials: drugs for rare diseases as essential medicines. Bulletin of the World Health Organisation. 2006; 84(9):745-51.
53. Drummond M, Towse A. Orphan drug policies: a suitable case for treatment. The European Journal of Health Economics. 2014; 15(4):335-40. doi: 10.1007/s10198-014-0560-1 PMID: 24435513
54. Kesselheim AS. Ethical considerations in orphan drug approval and use. Clinical Pharmacology and Therapeutics. 2012; 92(2):153-5. doi: 10.1038/clpt.2012.92 PMID: 22814660
55. Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments. Orphanet Journal of Rare Diseases. 2012; 7(74).
56. Simoens S, Cassiman D, Dooms M, Picavet E. Orphan drugs for rare diseases: is it time to revisit their special market access status? Drugs. 2012; 72:1437-43. doi: 10.2165/11635320-000000000-00000 PMID: 22747423
57. Mariz S, Tsigkos S, Fregonese L, Aarum S, Dehlink E, Llinares J, et al. The orphan framework as a new opportunity: an expert opinion. Expert Opinion on Orphan Drugs. 2014; 2(11):1181-6.
58. Picavet E, Dooms M, Cassiman D, Simoens S. Orphan Drugs for rare diseases: grounds for special status. Drug Development Research. 2012; 73(3):115-9.
59. Westermark K, Holm BB, Soderholm M, Llinares J, Riviere F, Aarum S, et al. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nature Reviews Drug Discovery. 2011; 10(5):341-9. doi: 10.1038/nrd3445 PMID: 21532564
60. Morel T, Arickx F, Befrits G, Siviero P, van der Meijden C, Xoxi E, et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet Journal of Rare Diseases. 2013; 8 (198).
61. Llinares J. A regulatory overview about rare diseases. In: Posada de la Paz M, Groft SC, editors. Rare diseases epidemiology: Springer Netherlands; 2010. p. 193-207.
62. Joppi R, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. European Journal of clinical pharmacology. 2013; 69(4):1009-24. doi: 10.1007/s00228-012-1423-PMID: 23090701
63. Lu CY, Lupton C, Rakowsky S, Babar ZU, Ross-Degnan D, Wagner AK. Patient access schemes in Asia-pacific markets: current experience and future potential. Journal of Pharmaceutical Policy and Practice. 2015; 8(1).